Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine

Molecular Pharmacology

Volumn 79, Issue 2, 2011, Pages 290-297

  Xue, Liu ^a   Ko, Mei Chuan ^b   Tong, Min ^a   Yang, Wenchao ^a   Hou, Shurong ^a   Fang, Lei ^a   Liu, Junjun ^a   Zheng, Fang ^a   Woods, James H ^b   Tai, Hsin Hsiung ^a   Zhan, Chang Guo ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; COCAINE; COMPLEMENTARY DNA; DRUG METABOLIZING ENZYME; LENTIVIRUS VECTOR; MUTANT PROTEIN; PLASMID DNA; RECOMBINANT CHOLINESTERASE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG DESIGN; DRUG DETOXIFICATION; DRUG HYDROLYSIS; DRUG OVERDOSE; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; LARGE SCALE PRODUCTION; LETHAL DOSE; LETHALITY; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SURVIVAL;

ACETYLCHOLINE; ANIMALS; BUTYRYLCHOLINESTERASE; COCAINE; HUMANS; HYDROGEN BONDING; MALE; METABOLIC DETOXICATION, DRUG; MICE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; RECOMBINANT PROTEINS;

EID: 78650634444     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068494     Document Type: Article

References (42)

1. Barber KL, Mesulam MM, Kraft GA, and Klein WL (1996) Butyrylcholinesterase alters the aggregation of β amyloid. Soc Neurosci Abstr 22:1172.
2. Braman J, Papworth C, and Greener A (2000) Site-Directed Mutagenesis Using Double-Stranded Plasmid DNA Templates, in The Nucleic Acid Protocols Handbook (Rapley R ed) pp 835-844, Humana Press, Totowa, NJ.
3. Brim RL, Nance MR, Youngstrom DW, Narasimhan D, Zhan CG, Tesmer JJ, Sunahara RK, and Woods JH (2010) A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol 77:593-600.
4. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, and Carroll ME (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33:2715-2725.
5. Carrera MR, Kaufmann GF, Mee JM, Meijler MM, Koob GF, and Janda KD (2004) Treating cocaine addiction with viruses. Proc Natl Acad Sci USA 101:10416-10421.
6. Case DA, Darden TA, TE Cheatham I, Simmerling CL, J. Wang RED, R Luo, Merz KM, Wang B, Pearlman DA, Crowle M, Brozell S, Tsui V, Gohlke H, J Mongan, Hornak V, Cui G, Beroza P, Schafmeister C, Caldwell JW, Ross WS, and Kollman PA (2004) AMBER 8, University of California, San Francisco.
7. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, Zhan CG, and Woods JH (2009) Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther 331:445-455.
8. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, and Woods JH (2006) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70:1885-1891.
9. Darvesh S, Hopkins DA, and Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131-138.
10. Gao D, Cho H, Yang W, Pan Y, Yang G, Tai HH, and Zhan CG (2006) Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl 45:653-657.
11. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, and Zhan CG (2009) Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75:318-323.
12. Gao D and Zhan CG (2005) Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J Phys Chem B 109:23070-23076.
13. Gao D and Zhan CG (2006) Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins 62:99-110.
14. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, and Brimijoin S (2008) An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 175:83-87.
15. Gatley SJ (1991) Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 41:1249-1254.
16. Giacobini E (2003) Butyrylcholinesterase: Its Function and Inhibitors, Martin Dunitz, London.
17. Gorelick DA (1997) Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48:159-165.
18. Gorelick DA (2008) Pharmacokinetic approaches to treatment of drug addiction. Expert Rev Clin Pharmacol 1:277-290.
19. Guillozet AL, Smiley JF, Mash DC, and Mesulam MM (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909-918.
20. Hamza A, Cho H, Tai HH, and Zhan CG (2005) Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B 109:4776-4782.
21. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, and Dean RA (1996) Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 279:713-717. (Pubitemid 27166843)
22. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, et al. (2008) New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11:425-438.
23. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper ZD, and Woods JH (2007) Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther 320:926-933. (Pubitemid 46147977)
24. Landry DW, Zhao K, Yang GX, Glickman M, and Georgiadis TM (1993) Antibody-catalyzed degradation of cocaine. Science 259:1899-1901.
25. Mack A and Robitzki A (2000) The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′butyrylcholinesterase- DNA study. Prog Neurobiol 60:607-628. (Pubitemid 30100400)
26. Masson P, Xie W, Froment MT, Levitsky V, Fortier PL, Albaret C, and Lockridge O (1999) Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta 1433:281-293.
27. Meijler MM, Kaufmann GF, Qi L, Mee JM, Coyle AR, Moss JA, Wirsching P, Matsushita M, and Janda KD (2005) Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc 127:2477-2484.
28. Narasimhan D, Nance MR, Gao D, Ko MC, Macdonald J, Tamburi P, Yoon D, Landry DM, Woods JH, Zhan CG, et al. (2010) Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel 23:537-547.
29. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, and Zhan CG (2005) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 102:16656-16661.
30. Pan Y, Gao D, Yang W, Cho H, and Zhan CG (2007) Free energy perturbation (FEP) Simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc 129:13537-13543.
31. Pan Y, Gao D, and Zhan CG (2008) Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc 130:5140-5149. (Pubitemid 351537074)
32. Sun H, Pang YP, Lockridge O, and Brimijoin S (2002a) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 62:220-224.
33. Sun H, Shen ML, Pang YP, Lockridge O, and Brimijoin S (2002b) Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther 302:710-716. (Pubitemid 34787239)
34. United Nations Office on Drugs and Crime (2010) World Drug Report 2010, United Nations Publication, Sales no. E.10.XI.13, New York, NY.
35. Xi ZX and Gardner EL (2008) Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev 1:303-327.
36. Yang W, Pan Y, Zheng F, Cho H, Tai HH, and Zhan CG (2009) Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J 96:1931-1938.
37. Yang W, Xue L, Fang L, Chen X, and Zhan CG (2010) Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact 187:148-152.
38. Zhan CG, Deng SX, Skiba JG, Hayes BA, Tschampel SM, Shields GC, and Landry DW (2005) First-principle studies of intermolecular and intramolecular catalysis of protonated cocaine. J Comput Chem 26:980-986.
39. Zhan CG and Gao D (2005) Catalytic mechanism and energy barriers for butyryl-cholinesterase- catalyzed hydrolysis of cocaine. Biophys J 89:3863-3872.
40. Zhan CG, Zheng F, and Landry DW (2003) Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc 125:2462-2474. (Pubitemid 36512233)
41. Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH, and Zhan CG (2008) Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130:12148-12155.
42. Zheng F, Yang W, Xue L, Hou S, Liu J, and Zhan CG (2010) Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry 49:9113-9119.